Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 5Sarcoma 3Genitourinary 3Breast 3Other solid neoplasm 2Gastrointestinal 2Dermatologic 2CNS 2Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1

Conditions

Solid Tumors, KRAS Mutation 1KRAS p.G12C Mutant Advanced Solid Tumors 1

Interventions

pembrolizumab 75Injections 67Carboplatin 38Pemetrexed 29Cisplatin 29Nivolumab 27Specimen Handling 24Interviews as Topic 24Cyclophosphamide 24atezolizumab 21tislelizumab 20Bevacizumab 20Paclitaxel 19Standard of Care 16Practice Guidelines as Topic 16fludarabine 15Docetaxel 15toripalimab 14Ipilimumab 14Educational Status 14Cetuximab 14Fluorouracil 13Oxaliplatin 12Etoposide 12olaparib 11durvalumab 11Methods 11Gemcitabine 11Early Intervention, Educational 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Midazolam × Other solid neoplasm × 1 year × Clear all
NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Amgen

Phase 1/2 Active not recruiting
713 enrolled 1 FDA
Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

NCT04973163 2026-02-17

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Boehringer Ingelheim

Phase 1 Active not recruiting
30 enrolled
Other solid neoplasm

Solid Tumors, KRAS Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡